Press Release

Antifungal Drugs Market Size to Witness CAGR of 4.0% from 2019-2025
October 2020

Antifungal Drugs Market Size to Witness CAGR of 4.0% from 2019-2025

According to iCognition Insights, the global antifungal drugs market size was estimated to be USD 12.30 billion in 2019. Major factors responsible for the growth of this market are increase in hospital-acquired infections; rising awareness about fungal infections on the skin, mouth, eye & vagina; easy access of over-the-counter drugs, and public-private partnership in the pharmaceutical industry. However, factors such as increasing approvals for generic drugs, patent expiration of innovator drugs, and rising counterfeit drugs are responsible for restraining the market growth.

Based on drug type, the market is segmented into azoles, echinocandins, allylamines, and polyenes. In 2019, the azoles antifungal drug class held the dominant position in the market with leading therapeutics drugs such as Noxafil, Cresemba, Vfend, and Diflucan. Based on therapeutic indication, the market is categorized into aspergillosis, dermatophytosis, and candidiasis. In 2019, dermatophytosis segment accounted for the highest revenue share due to increasing skin infection cases.

In 2019, North America held a dominant position in terms of revenue and is anticipated to hold its dominance over the forecast period. This is attributed to rising prevalence of infectious diseases and hospital-acquired infections. Major market players in the North American region are increasing their efforts on R&D investment and focussing on clinical trials for novel innovative drug developments.

Some of the key players in the Antifungal Drugs Market are Pfizer (U.S.), Merck & Co.  (U.S.), GlaxoSmithKline (UK), Astellas Pharma (Japan), Bayer (Germany), Sanofi (France), Novartis Switzerland, Gilead Sciences (U.S.), Abbott Laboratories (U.S.), and Scynexis (U.S.).

Antifungal Drugs Market: Key Datapoints-

  • Increase in hospital-acquired infections and rising awareness about fungal infections are boosting the market growth
  • Rising approvals for generic drugs, patent expiration of innovator drugs, and increasing counterfeit drugs are hindering the market growth
  • Candidiasis is a most common blood stream fungal infection caused by yeast and it is expected to show fastest CAGR over the forecast period
  • Asia Pacific is projected to show highest CAGR over the forecast period due to presence of a large populations base, availability of antifungal drugs, and high unmet clinical needs
  • The major players operating in the antifungal drug market are adopting growth strategies such as new product development, and mergers & acquisitions to increase their global market reach

Antifungal Drugs Market, By Drug Type (Revenue, 2017-2025, USD Billion)

  • Azoles
    • Triazoles
      • Fluconazole
      • Itraconazole
      • Voriconazole
      • Posaconazole
      • Isavuconazole
    • Imidazoles
      • Ketoconazole
    • Echinocandins
      • Micafungin (Mycamine)
      • Caspofungin ( Cancidas)
      • Anidulafungin (Eraxis)
  • Allylamines
    • Naftifine
    • Terbinafine
  • Polyenes
    • Amphotericin
    • Nystatin
    • Candicidin

Antifungal Drugs Market, By Therapeutic Indication (Revenue, 2017-2025, USD Billion)

  • Aspergillosis
  • Dermatophytosis
  • Candidiasis
  • Oral
  • Vaginal
  • Vulvovaginal (VVC)
  • Esophageal

Antifungal Drugs Market, By Region (Revenue, 2017-2025, USD Billion)

  • North America
    • US
    • Canada
  • Europe
    • Germany
    • France
    • UK
    • Spain
    • Italy
    • Russia
    • Rest of Europe
  • Asia Pacific
    • China
    • Japan
    • India
    • Australia
    • South Korea
    • Rest of APAC
  • Latin America
    • Brazil
    • Mexico
    • Argentina
    • Rest of LATAM
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • Rest of MEA

Request a free sample copy or view report summary:

Antifungal Drugs Market